Insulin access and affordability in the USA: anticipating the first interchangeable insulin product

Lancet Diabetes Endocrinol. 2020 May;8(5):360-362. doi: 10.1016/S2213-8587(20)30105-4. Epub 2020 Mar 20.

Authors

Jing Luo¹, Aaron S Kesselheim², Ameet Sarpatwari²

Affiliations

¹ Division of General Internal Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA. Electronic address: luoj@pitt.edu.
² Program on Regulation, Therapeutics, And Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

No abstract available

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Biosimilar Pharmaceuticals / therapeutic use
Costs and Cost Analysis
Drug Costs*
Drugs, Generic / therapeutic use
Health Services Accessibility*
Humans
Insulin / economics*
Insulin / therapeutic use
United States

Substances

Biosimilar Pharmaceuticals
Drugs, Generic
Insulin

Grant support

KL2 TR001856/TR/NCATS NIH HHS/United States